Abstract
Pathological, genetic, biochemical and pharmacological studies support the hypothesis that brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimers disease (AD). Drugs currently used for the treatment of AD produce limited clinical benefits and do not treat the underlying causes of the disease. In the last 10 years, new therapeutic approaches targeting Aβ have been discovered and developed with the hope of modifying the natural history of the disease. Several active and passive immunotherapy approaches are under investigation in clinical trials with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that is being tested in two large late-stage trials. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. Unfortunately, the most biologically attractive of these proteases, β-secretase, that regulates the first step of the amyloidogenic APP metabolism, was found to be particularly problematic to block and only one compound (CTS21166) has reached clinical testing so far. Conversely, several inhibitors of β-secretase, the protease that regulates the last metabolic step generating Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in Phase III clinical development. Compounds that stimulate β-secretase, the enzyme responsible for the nonamyloidogenic metabolism of APP, are also being developed one of them, EHT-0202, has recently started a Phase II study. Furthermore, brain penetrant inhibitors of Aβ aggregation have been identified and one of such compounds, PBT-2, has produced encouraging neuropsychological results in a recently completed Phase II study. With all these anti-Aβ approaches in clinical testing, we will know in few years if the Av hypothesis of AD is correct.
Keywords: β-Amyloid, Alzheimer's disease, active immunotherapy, passive immunotherapy, α-secretase activators, γ-secretase inhibitors, γ-secretase modulators, β-secretase inhibitors
Current Alzheimer Research
Title: Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid
Volume: 7 Issue: 1
Author(s): V. Frisardi, V. Solfrizzi, B. P. Imbimbo, C. Capurso, A. D'Introno, A. M. Colacicco, G. Vendemiale, D. Seripa, A. Pilotto, A. Capurso and F. Panza
Affiliation:
Keywords: β-Amyloid, Alzheimer's disease, active immunotherapy, passive immunotherapy, α-secretase activators, γ-secretase inhibitors, γ-secretase modulators, β-secretase inhibitors
Abstract: Pathological, genetic, biochemical and pharmacological studies support the hypothesis that brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimers disease (AD). Drugs currently used for the treatment of AD produce limited clinical benefits and do not treat the underlying causes of the disease. In the last 10 years, new therapeutic approaches targeting Aβ have been discovered and developed with the hope of modifying the natural history of the disease. Several active and passive immunotherapy approaches are under investigation in clinical trials with the aim of accelerating Aβ clearance from the brain of the AD patients. The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-Aβ monoclonal antibodies, that is being tested in two large late-stage trials. Compounds that interfere with proteases regulating Aβ formation from amyloid precursor protein (APP) are also actively pursued. Unfortunately, the most biologically attractive of these proteases, β-secretase, that regulates the first step of the amyloidogenic APP metabolism, was found to be particularly problematic to block and only one compound (CTS21166) has reached clinical testing so far. Conversely, several inhibitors of β-secretase, the protease that regulates the last metabolic step generating Aβ, have been identified, the most advanced being LY-450139 (semagacestat), presently in Phase III clinical development. Compounds that stimulate β-secretase, the enzyme responsible for the nonamyloidogenic metabolism of APP, are also being developed one of them, EHT-0202, has recently started a Phase II study. Furthermore, brain penetrant inhibitors of Aβ aggregation have been identified and one of such compounds, PBT-2, has produced encouraging neuropsychological results in a recently completed Phase II study. With all these anti-Aβ approaches in clinical testing, we will know in few years if the Av hypothesis of AD is correct.
Export Options
About this article
Cite this article as:
Frisardi V., Solfrizzi V., Imbimbo P. B., Capurso C., D'Introno A., Colacicco M. A., Vendemiale G., Seripa D., Pilotto A., Capurso A. and Panza F., Towards Disease-Modifying Treatment of Alzheimers Disease: Drugs Targeting β -Amyloid, Current Alzheimer Research 2010; 7 (1) . https://dx.doi.org/10.2174/156720510790274400
DOI https://dx.doi.org/10.2174/156720510790274400 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Etiology of the Metabolic Syndrome
Current Cardiology Reviews Functional Roles of Synaptic and Extrasynaptic NMDA Receptors in Physiological and Pathological Neuronal Activities
Current Drug Targets Identification of Structural and Electronic Features for a Series of MCH1R Antagonists
Medicinal Chemistry Targeting Endogenous Mu- and Delta-Opioid Receptor Systems for the Treatment of Drug Addiction
CNS & Neurological Disorders - Drug Targets Peptide Immunotherapies in Type 1 Diabetes: Lessons from Animal Models
Current Medicinal Chemistry Prevalence of Neuropsychiatric Symptoms in Alzheimers Disease and Vascular Dementia
Current Alzheimer Research Nucleus Accumbens Dopamine and the Forebrain Circuitry Involved in Behavioral Activation and Effort-Related Decision Making: Implications for Understanding Anergia and Psychomotor Slowing in Depression
Current Psychiatry Reviews FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry Commentary (Research Highlights)
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Nitric Oxide Synthases and Their Inhibitors)
Current Enzyme Inhibition The Wnt Pathway: Emerging Anticancer Strategies
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery A Practical Comprehensive Approach to Management of Acute Decompensated Heart Failure
Current Cardiology Reviews Editorial (Thematic Issue: Emerging Targets for Stimulant Use Disorders: Where To Invest In An Era Of Constrained Resources?)
CNS & Neurological Disorders - Drug Targets Neuroprotective Potential of Adenyl Cyclase/cAMP/CREB and Mitochondrial CoQ10 Activator in Amyotrophic Lateral Sclerosis Rats
Current Bioactive Compounds Mitogen Activated Protein (MAP) Kinases: Development of ATP and Non- ATP Dependent Inhibitors
Medicinal Chemistry Multi-Faceted Arginine: Mechanism of the Effects of Arginine on Protein
Current Protein & Peptide Science Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Anti-Cytokine Therapeutics: History and Update
Current Pharmaceutical Design The Role of Corticotropin-Releasing Hormone in the Pathophysiology of Depression: Therapeutic Implications
Current Topics in Medicinal Chemistry